Visualisation of neuroblastoma growth in a Scid mouse model using [18F]FDG and [18F]FLT-PET

Anticancer Res. 2006 Sep-Oct;26(5A):3467-72.

Abstract

Background: Tumor therapy has been monitored using the metabolic indicator [18F]fluorodeoxyglucose ([18F]FDG). However, the nucleotide precursor [18F]fluoro-thymidine ([18F]FLT) is in principle more specific as it is incorporated into DNA. Thus, the [18F]FDG and [18F]FLT uptake by human neuroblastomas grown in Scid mice are compared in this study.

Materials and methods: Scid mice were inoculated with human neuroblastoma cells. Tumor imaging was performed with a human whole-body full-ring PET scanner. Furthermore, the tumor weight and the cell proliferation rate were determined.

Results: Neuroblastomas could be visualised using [18F]FDG in 40% and with [18F]FLT in 70% of the cases. [18F]FDG or [18F]FLT uptake could not be visualised in neuroblastomas less than 1.0 g in weight. No correlation between the cell proliferation rate and tracer uptake could be detected.

Conclusion: [18F]FLT showed a higher uptake than [18F]FDG and, therefore, might be more suitable for monitoring anticancer therapy, at least in this tumor model.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation
  • Dideoxynucleosides*
  • Disease Models, Animal*
  • Feasibility Studies
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Neoplasm Staging
  • Neuroblastoma / diagnostic imaging*
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*
  • Survival Rate
  • Whole Body Imaging

Substances

  • Dideoxynucleosides
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18